Anti–PD-1/PD-L1 antibodies in non-small cell lung cancer: the era of immunotherapy
Citations
233 citations
Cites background from "Anti–PD-1/PD-L1 antibodies in non-s..."
...Antibodies against PD-1/PD-L1 prevent this interaction, thereby leading to T cell activation and thus acting as an immunotherapy against tumor cells (Valecha et al., 2017)....
[...]
97 citations
96 citations
Cites background from "Anti–PD-1/PD-L1 antibodies in non-s..."
...In contrast, immunotherapy agents, such as those targeting the PD-1 pathway, have demonstrated clinical activity in patients by reactivating preexisting antitumor immune responses (38) but only benefit a subset of patients....
[...]
85 citations
Cites background from "Anti–PD-1/PD-L1 antibodies in non-s..."
...Immune checkpoint inhibitors are currently in the spotlight as promising therapeutics for advanced non-small cell lung cancer (NSCLC).(1,2) Among these drugs, nivolumab and pembrolizumab, which are classified as blockade for programmed celldeath protein 1 (PD-1) were recently approved as standard drugs for subsequent treatment of NSCLC patients by FDA....
[...]
81 citations
References
14,664 citations
10,674 citations
7,474 citations
6,869 citations
6,812 citations